# Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis

> **NCT02277574** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 29 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** AMP-110
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02277574
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-01
- **Final completion:** 2015-07
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2016-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02277574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02277574, "Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02277574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*